Page last updated: 2024-10-24

ossification involved in bone maturation

Definition

Target type: biologicalprocess

The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone, involved in the progression of the skeleton from its formation to its mature state. [GOC:dph, GOC:mah, GOC:mtg_mpo]

Ossification, also known as bone formation, is a complex biological process that involves the development and growth of bone tissue. It begins during fetal development and continues throughout life, albeit at a slower pace after puberty. There are two primary types of ossification: intramembranous ossification and endochondral ossification.

**Intramembranous Ossification**
This process occurs directly within mesenchymal connective tissue, which is a type of embryonic tissue. It is responsible for forming flat bones, such as the bones of the skull, clavicle, and parts of the mandible. The process involves the following steps:
1. **Mesenchymal cells differentiate into osteoblasts:** Osteoblasts are specialized cells that produce the organic matrix of bone, called osteoid.
2. **Osteoid production and mineralization:** Osteoblasts deposit osteoid, which then becomes mineralized by the deposition of calcium salts. This forms bony spicules.
3. **Formation of trabeculae:** The bony spicules fuse together to form a network of trabeculae, which are interconnected bony plates.
4. **Development of periosteum:** A periosteum, a fibrous membrane that surrounds the bone, develops.

**Endochondral Ossification**
This process begins with a hyaline cartilage model, which is then replaced by bone tissue. It is responsible for forming most bones in the body, including long bones. The process involves the following steps:
1. **Formation of a cartilage model:** Mesenchymal cells condense and differentiate into chondroblasts, which produce hyaline cartilage.
2. **Chondrocyte growth and proliferation:** Chondrocytes within the cartilage model proliferate and enlarge.
3. **Calcification of the cartilage matrix:** The cartilage matrix begins to calcify, trapping chondrocytes and leading to their death.
4. **Invasion of blood vessels and osteoblasts:** Blood vessels invade the calcified cartilage, bringing with them osteoblasts.
5. **Formation of primary ossification center:** Osteoblasts lay down bone tissue on the calcified cartilage matrix, forming a primary ossification center.
6. **Secondary ossification centers:** In long bones, secondary ossification centers form in the epiphyses (ends of the bone).
7. **Formation of epiphyseal plate:** A layer of cartilage, called the epiphyseal plate, remains between the primary and secondary ossification centers. This plate is responsible for longitudinal bone growth.
8. **Bone remodeling:** Once the bone has reached its full size, the epiphyseal plate closes and bone remodeling continues throughout life to maintain bone strength and repair damage.

**Factors Affecting Ossification**
Several factors can influence the process of ossification, including:
* **Genetics:** Genes play a crucial role in determining bone growth and development.
* **Hormones:** Hormones like growth hormone, thyroid hormone, and sex hormones are essential for bone growth and maturation.
* **Nutrition:** Adequate intake of calcium, vitamin D, and other nutrients is vital for bone formation.
* **Mechanical stress:** Physical activity and weight-bearing exercise stimulate bone growth and density.

**Bone Maturation and Remodeling**
Bone growth and maturation continue until adulthood, when the epiphyseal plates close. After puberty, the skeleton reaches its peak bone mass. However, bone remodeling continues throughout life.
* **Bone resorption:** Osteoclasts, specialized cells that break down bone tissue, are responsible for resorption.
* **Bone deposition:** Osteoblasts, the bone-building cells, are responsible for deposition.

These processes are constantly balancing to maintain bone strength and density, adapting to changing needs and stresses.
'"

Proteins (3)

ProteinDefinitionTaxonomy
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseA 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15125]Homo sapiens (human)
Transforming protein RhoAA GTP-binding protein RhoA that is encoded in the genome of human. [PRO:CNA, UniProtKB:P61586]Homo sapiens (human)
Ryanodine receptor 1A ryanodine receptor 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P21817]Homo sapiens (human)

Compounds (28)

CompoundDefinitionClassesRoles
amiodaroneamiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound
cardiovascular drug
buflomedilbuflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structurearomatic ketone
haloperidolhaloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
nafoxidineNafoxidine: An estrogen antagonist that has been used in the treatment of breast cancer.benzenes;
naphthalenes;
ring assembly
nevirapinenevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
cyclopropanes;
dipyridodiazepine
antiviral drug;
HIV-1 reverse transcriptase inhibitor
raloxifeneraloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
trifluoperazineN-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines
antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trifluperidolTrifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)aromatic ketone
corticosterone11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone
human metabolite;
mouse metabolite
triparanolTriparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.stilbenoidanticoronaviral agent
1,3-ditolylguanidine1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the braintoluenes
opipramolOpipramol: A tricyclic antidepressant with actions similar to AMITRIPTYLINE.dibenzoazepine
jervinejervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structurepiperidines
naftifinenaftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.

naftifine: allylamine der; RN given refers to unlabeled parent cpd
allylamine antifungal drug;
naphthalenes;
tertiary amine
EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
carbizocaine
fenpropimorphalkylbenzene
chrysamine gchrysamine G: structure given in first source; RN refers to disodium salt
preclamol
enclomipheneEnclomiphene: The trans or (E)-isomer of clomiphene.
zuclomipheneZuclomiphene: The cis or (Z)-isomer of clomiphene.stilbenoid
terbinafineacetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine
EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
bm 15766BM 15766: 7-dehydrocholesterol reductase antagonist
bastadin 5
ne 100
sa 4503
bastadin 4
ccg-203971